NCT04230408 - Intensified Chemo-immuno-radiotherapy With Durvalumab for Stage III Non-Small Cell Lung Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 5, 2021

Primary Completion Date

October 7, 2024

Study Completion Date

December 20, 2024

Conditions

Lung Neoplasms

Interventions

DRUG

Durvalumab

Intensified chemo-immuno-radiotherapy with durvalumab in combination with carboplatin, paclitaxel and radiation

Trial Locations (6)

INCA, Rio de Janeiro

CPO, Porto Alegre

COI Américas, Rio de Janeiro

Beneficiencia Portuguesa de São Paulo/Hospital São José, São Paulo

ICESP, São Paulo

Liga Norte Riograndense Contra o Câncer, Natal